Molecular Partners AG (OTCMKTS:MLLCF – Get Free Report) was up 11.1% on Thursday . The stock traded as high as $5.00 and last traded at $5.00. Approximately 700 shares changed hands during mid-day trading, an increase of 44% from the average daily volume of 485 shares. The stock had previously closed at $4.50.
Molecular Partners Stock Performance
The business has a 50 day moving average of $5.23 and a 200-day moving average of $5.89.
Molecular Partners Company Profile
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Read More
- Five stocks we like better than Molecular Partners
- Why Are Stock Sectors Important to Successful Investing?
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- How is Compound Interest Calculated?
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- 5 Top Rated Dividend Stocks to Consider
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
